[
  {
    "ts": "2026-02-19T07:09:38+00:00",
    "headline": "Evaluating Bio-Techne (TECH) After Ella’s CE-IVD Milestone And Diagnostics Growth Prospects",
    "summary": "CE-IVD certification puts Ella in focus for Bio-Techne investors Bio-Techne (TECH) just secured CE-IVD marking for its Ella benchtop immunoassay platform in the European Union, opening the door for clinical labs and assay developers to adopt the system. For you as an investor, the key question is how this regulatory milestone, combined with recent management changes in the Diagnostics and Spatial Biology segment, might influence the company’s positioning in clinical diagnostics and its...",
    "url": "https://finance.yahoo.com/news/evaluating-bio-techne-tech-ella-070938339.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2dc8c4ce-9916-3dc2-b7a9-d25e1ce2cd09",
      "content": {
        "id": "2dc8c4ce-9916-3dc2-b7a9-d25e1ce2cd09",
        "contentType": "STORY",
        "title": "Evaluating Bio-Techne (TECH) After Ella’s CE-IVD Milestone And Diagnostics Growth Prospects",
        "description": "",
        "summary": "CE-IVD certification puts Ella in focus for Bio-Techne investors Bio-Techne (TECH) just secured CE-IVD marking for its Ella benchtop immunoassay platform in the European Union, opening the door for clinical labs and assay developers to adopt the system. For you as an investor, the key question is how this regulatory milestone, combined with recent management changes in the Diagnostics and Spatial Biology segment, might influence the company’s positioning in clinical diagnostics and its...",
        "pubDate": "2026-02-19T07:09:38Z",
        "displayTime": "2026-02-19T07:09:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Ih9Jyeb4E8RAOq22ZtFHA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r5jgPUxQrxmcesBmGBKgkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/evaluating-bio-techne-tech-ella-070938339.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/evaluating-bio-techne-tech-ella-070938339.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TECH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]